{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:44:30Z","timestamp":1791812670324,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,12]],"date-time":"2027-10-12T00:00:00Z","timestamp":1823299200000},"content-version":"am","delay-in-days":590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["akdh.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.akdh.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:33:45Z","timestamp":1783024425000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?"],"prefix":"10.1053","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-6892","authenticated-orcid":false,"given":"Ekamol","family":"Tantisattamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.akdh.2026.02.003_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.109.129841","article-title":"Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006","volume":"54","author":"Plantinga","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.akdh.2026.02.003_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjmed.2007.11.025","article-title":"Hypertension awareness, treatment, and control in chronic kidney disease","volume":"121","author":"Sarafidis","year":"2008","journal-title":"Am J Med"},{"issue":"7 Suppl 2","key":"10.1053\/j.akdh.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.ASN.0000070145.00225.EC","article-title":"Patterns of care for patients with chronic kidney disease in the United States: dying for improvement","volume":"14","author":"Owen","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2026.02.003_bib4","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1053\/j.akdh.2026.02.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/VHRM.S292522","article-title":"How do I manage hypertension in patients with advanced chronic kidney disease not on dialysis? Perspectives from clinical practice","volume":"17","author":"Polychronopoulou","year":"2021","journal-title":"Vasc Health Risk Manag"},{"issue":"14","key":"10.1053\/j.akdh.2026.02.003_bib6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.mnh.0000444912.40418.45","article-title":"Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease","volume":"23","author":"Weir","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"10.1053\/j.akdh.2026.02.003_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/j.ajkd.2021.03.019","article-title":"Risk of potentially inappropriate medications in adults with CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"78","author":"Hall","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2026.02.003_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"22","key":"10.1053\/j.akdh.2026.02.003_bib13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.akdh.2026.02.003_bib10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"13","key":"10.1053\/j.akdh.2026.02.003_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.akdh.2026.02.003_bib15","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney DiseaseResults from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"38","key":"10.1053\/j.akdh.2026.02.003_bib51","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1053\/j.akdh.2026.02.003_bib11","first-page":"596","article-title":"Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1053\/j.akdh.2026.02.003_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/jamainternmed.2015.6403","article-title":"Exclusion of patients with kidney disease from cardiovascular trials","volume":"176","author":"Ishida","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ajkd.2021.09.013","article-title":"KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD","volume":"79","author":"Drawz","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.akdh.2026.02.003_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"issue":"10449","key":"10.1053\/j.akdh.2026.02.003_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.akdh.2026.02.003_bib20","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2026.02.003_bib21","article-title":"Blood pressure targets for the treatment of people with hypertension and cardiovascular disease","volume":"9","author":"Saiz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1681\/ASN.0000000000000072","article-title":"Intensive BP control in patients with CKD and risk for adverse outcomes","volume":"34","author":"Ku","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/ckj\/sfac014","article-title":"Blood pressure targets in CKD 2021: the never-ending guidelines debacle","volume":"15","author":"Carriazo","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.ajkd.2024.08.010","article-title":"Intensive home blood pressure lowering in patients with advanced CKD","volume":"85","author":"Ku","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"10.1053\/j.akdh.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2026.02.003_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","article-title":"Use of renin-angiotensin system blockade in advanced CKD: an NKF-KDOQI controversies report","volume":"72","author":"Weir","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.akdh.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2215\/CJN.10611015","article-title":"Antihypertensive medication use in older patients transitioning from chronic kidney disease to end-stage renal disease on dialysis","volume":"11","author":"Chang","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2026.02.003_bib28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-Converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials","volume":"177","author":"Ku","year":"2024","journal-title":"Ann Intern Med"},{"issue":"27","key":"10.1053\/j.akdh.2026.02.003_bib29","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.akdh.2026.02.003_bib30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1053\/j.akdh.2026.02.003_bib31","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013Angiotensin System inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2026.02.003_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin System inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide Study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between Renin-Angiotensin System blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"15","key":"10.1053\/j.akdh.2026.02.003_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2026.02.003_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.akdh.2026.02.003_bib36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.akdh.2026.02.003_bib37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2026.02.003_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.akdh.2026.02.003_bib39","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2026.02.003_bib40","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2026.02.003_bib41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"issue":"12","key":"10.1053\/j.akdh.2026.02.003_bib42","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.akdh.2026.02.003_bib43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2026.02.003_bib44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"38","key":"10.1053\/j.akdh.2026.02.003_bib52","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfad183","article-title":"Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial","volume":"39","author":"Heerspink","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"10416","key":"10.1053\/j.akdh.2026.02.003_bib46","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"issue":"10367","key":"10.1053\/j.akdh.2026.02.003_bib47","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.akdh.2026.02.003_bib48","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.akdh.2026.02.003_bib49","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.akdh.2026.02.003_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:44:49Z","timestamp":1791809089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813926000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2949813926000273"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2026.02.003","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}